Brought to you by 
Speedel completes CHF71.3mm Series E round
12 Jan 2004
Executive Summary
In its mezzanine round, private cardiovascular drug developer Speedel has raised CHF52.1mm ($38.6mm) through DSM Venturing BV (DSM NV's business development arm) and the Novartis Venture Fund.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Speedel completes CHF71.3mm Series E round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice